Champions Oncology (NASDAQ:CSBR) Stock Price Down 1.8% – Time to Sell?

Shares of Champions Oncology, Inc. (NASDAQ:CSBR) traded down 1.8% during mid-day trading on Wednesday . The stock traded as low as $6.00 and last traded at $6.03. 3,485 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 9,735 shares. The stock had previously closed at $6.14.

Analyst Ratings Changes

Separately, Weiss Ratings cut Champions Oncology from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, March 16th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Champions Oncology currently has a consensus rating of “Sell”.

Champions Oncology Stock Performance

The company has a 50-day simple moving average of $6.13 and a 200-day simple moving average of $6.51. The company has a market cap of $83.74 million, a price-to-earnings ratio of -37.69 and a beta of 0.40.

Hedge Funds Weigh In On Champions Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Champions Oncology during the 2nd quarter worth approximately $103,000. Essex Investment Management Co. LLC acquired a new position in Champions Oncology during the 4th quarter worth approximately $126,000. Jane Street Group LLC acquired a new position in Champions Oncology during the 1st quarter worth approximately $200,000. Goldman Sachs Group Inc. acquired a new position in Champions Oncology during the 1st quarter worth approximately $201,000. Finally, Acadian Asset Management LLC increased its position in Champions Oncology by 28.7% during the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 8,814 shares during the period. Institutional investors and hedge funds own 41.30% of the company’s stock.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.